Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies

Cancer Science

Volumn 103, Issue 7, 2012, Pages 1290-1295

  Ogura, Michinori ^a   Tsukasaki, Kunihiro ^b   Nagai, Hirokazu ^c   Uchida, Toshiki ^a   Oyama, Takashi ^a   Suzuki, Tatsuya ^a   Taguchi, Jun ^b   Maruyama, Dai ^d   Hotta, Tomomitsu ^c   Tobinai, Kensei ^d  

^a NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; FORODESINE;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER PAIN; CANCER PATIENT; CANCER RELAPSE; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CUTANEOUS T CELL LYMPHOMA; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HERPES ZOSTER; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NK T CELL LYMPHOMA; OUTCOME ASSESSMENT; PERIPHERAL EDEMA; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT RESPONSE; VIRUS INFECTION; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; EXANTHEMA; FEMALE; HUMANS; LYMPHOMA, LARGE-CELL, ANAPLASTIC; LYMPHOMA, T-CELL; LYMPHOMA, T-CELL, PERIPHERAL; LYMPHOPENIA; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MYCOSIS FUNGOIDES; NATURAL KILLER T-CELLS; PURINE NUCLEOSIDES; PYRIMIDINONES; RECURRENCE; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84863330504     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02287.x     Document Type: Article

References (15)

1. Markert ML Purine nucleoside phosphorylase deficiency. Immunodefic Rev 1991; 3: 45-81.
2. Al-Kali A, Gandhi V, Ayoubi M, Keating M, Ravandi F Forodesine: review of preclinical and clinical data. Future Oncol 2010; 6: 1211-7.
3. Duvic M, Forero-Torres A, Foss F, Olsen E, Kim Y Response to oral forodesine in refractory cutaneous T-cell lymphoma: interim results of a phase I/II study (Abstract). Blood 2007; 110: Abstract 122.
4. Cheson BD, Horning SJ, Coiffier B et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244-53.
5. Olsen EA, Kim YH, Kuzel TM et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-15.
6. Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-22.
7. Pui CH, Evans WE Acute lymphoblastic leukemia. N Engl J Med 1998; 339: 605-15.
8. López-Guillermo A, Cid J, Salar A et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 1998; 9: 849-55.
9. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood 1998; 92: 76-82.
10. Vose J, Armitage J, Weisenburger D International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 2008; 26: 4124-30.
11. O'Connor OA, Pro B, Pinter-Brown L et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011; 29: 1182-9.
12. Prince HM, Duvic M, Martin A et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 1870-7.
13. Piekarz RL, Frye R, Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410-7.
14. Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485-91.
15. Yamamoto K, Utsunomiya A, Tobinai K et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010; 28: 1591-8.